MOST NOTEWORTHY:

• Halozyme (NASDAQ: HALO) was initiated with a Buy rating and $14 target at Oppenheimer. The firm is positive on Halozyme's prospects for signing additional multi-product Enhanze deals in the next 12 months and the company's expanding internal pipeline.

• Oppenheimer also initiated shares of Rosetta Genomics (NASDAQ: ROSG) with a Buy rating and $11 target, as the firm is positive on Rosetta's intellectual property position in the emerging microRNA field related to the development and commercialization of research, diagnostic and therapeutic products, and other applications.

• Goldman Sachs resumed coverage of U.S. Steel Group (NYSE: X) with a Neutral rating.

• BioFuel Energy (NASDAQ: BIOF) was initiated with a Neutral rating at Cowen, as the firm sees a lack of catalysts until the company's plants under construction come on line in Q108...

• Brightpoint (NASDAQ: CELL) was initiated with an Outperform rating and $18 target at Credit Suisse.

• MasterCard (NYSE: MA) was initiated with a Market Perform rating at Wachovia on valuation.

• Citigroup initiated shares of Signature Bank (NASDAQ: SBNY) with a Buy rating and $39 target and shares of Discover Financial Services (NYSE: DFS) with a Sell rating and $24 target.

• Pacific Growth Equities started shares of Altair Nanotechnologies (NASDAQ: ALTI) with a Neutral rating.

Analyst initiations 7-24-07: CELL, DFS, MA and X originally appeared on BloggingStocks on Tue, 24 Jul 2007 11:11:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY:

• Cowen believes AstraZeneca (NYSE: AZN) faces challenges from patent expirations, patent challenges, high-risk pipeline and value creation from deals, and initiated shares with a Neutral rating.

• Ametek (NYSE: AME) was initiated at Friedman Billings with an Outperform rating and $44 target, as the firm believes AME has turned into a collection of niche-oriented high-value-added manufacturers of precision instrumentation, resulting in a high-margin, high-return business with above average growth.

• InterNAP (NASDAQ: INAP) was initiated at Thomas Weisel with an Overweight rating, as the firm is positive on INAP's unique service offerings, VitalSteam acquisition opportunities, high growth customers, and improving collocation and bandwidth demand fundamentals.

• Cantor expects Rosetta Genomics (NASDAQ: ROSG) to launch the world's first microRNA-based cancer diagnostic in the second-half of 2008 with a market of $200 million, and initiated shares with a Buy rating and $15 target.

• Banc of America initiated shares of Spirit AeroSystems Holdings (NYSE: SPR) with a Buy rating and $42 target.

• Duke Energy (NYSE: DUK) was initiated with a Market Perform rating at BMO Capital.

• Merrill Lynch initiated shares of JMP Group (NYSE: JMP) with a Buy rating.

• UBS initiated shares of Itron (NASDAQ: ITRI) with a Neutral rating and $82 target.

Analyst initiations 6-28-07: AZN, DUK, JMP and SPR originally appeared on BloggingStocks on Thu, 28 Jun 2007 11:13:00 EST. Please see our terms for use of feeds.